Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Paravertebral Block, General Anesthesia; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: PTSD
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Health Volunteers
Interventions: Midazolam, CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Interaction Drug Food
Interventions: goldenseal, Metformin, Furosemide, Midazolam oral solution, Rosuvastatin Oral Tablet; Dietary Supplement · Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Solid Tumors
Interventions: tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam; Drug · Dietary Supplement
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Interaction
Interventions: Oregano, Drug cocktail; Dietary Supplement · Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Solid Tumours
Interventions: CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Postoperative Pain
Interventions: Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Healthy
Interventions: PBI-4050 and midazolam; Drug
Lead sponsor: Liminal BioSciences Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Le Fort, Pain, Postoperative
Interventions: Standardized Anesthetic Course from Premedication to Induction; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Male Volunteer
Interventions: JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: HIV Infections
Interventions: VH4011499, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Cataract
Interventions: MELT-300, Midazolam alone, Ketamine alone, Placebo; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota

Conditions: Healthy, No Evidence of Disease
Interventions: garlic powder tablets, oxycodone; Dietary Supplement · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 21 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer
Interventions: Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab); Drug · Other · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more

Conditions: Procedural Sedation, Endoscopy
Interventions: CNS 7056, Midazolam; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 4 more

Conditions: Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 1,394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more

Conditions: Agitation
Interventions: Ketamine-based protocol, Midazolam-based protocol; Other
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Tonsillectomy
Interventions: Rocuronium, Sugammadex, Anesthesia without neuromuscular blockade; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Continuous Subpleural Infusion of Bupivacaine

Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Anesthetic Optimization in Pediatric LeFort Surgeries

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

Effects of Garlic Supplements on Opioids in Healthy Volunteers

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Ketamine Versus Midazolam for Prehospital Agitation

Muscle Relaxation for Pediatric Adenotonsillectomy